Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01782742 · ClinicalTrials.gov registry record · Phase 2
Bexarotene Amyloid Treatment for Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01782742 is a Phase 2 study of Alzheimers Disease that has completed, run by The Cleveland Clinic. The registered enrollment target is 20 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01782742, a Phase 2 study of Alzheimers Disease, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Retinoid X receptors (RXR) are nuclear receptors that have been linked to numerous metabolic pathways relevant to Alzheimer's disease (AD) and Aβ (harmful protein) production and removal. The study drug "bexarotene" is an FDA approved anti-cancer agent but is not approved for use in Alzheimer's disease. Bexarotene acts as an RXR agonist that has reduced Aβ (harmful protein) in the brain in experimental models of Alzheimer's disease. This study aims to determine the safety and effect on abnormal proteins found in the brain (based on brain scans) of 300 mg of "bexarotene" administered for one month compared to placebo (inactive agent).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bexarotene
Study Locations (1)
Nevada
- Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01782742
The ClinicalTrials.gov registry entry for NCT01782742 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (100% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01782742 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.
Frequently Asked Questions
What is clinical trial NCT01782742 about?
NCT01782742 is a clinical study titled "Bexarotene Amyloid Treatment for Alzheimer's Disease". Retinoid X receptors (RXR) are nuclear receptors that have been linked to numerous metabolic pathways relevant to Alzheimer's disease (AD) and Aβ (harmful protein) production and removal. The study drug "bexarotene" is an FDA approved anti-cancer agent but is not approved for use in Alzheimer's dise...
What is the current status of trial NCT01782742?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-02. Estimated completion is 2014-12.
What conditions does trial NCT01782742 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01782742?
The interventions under investigation include: Placebo (DRUG), Bexarotene (DRUG).
Who is sponsoring clinical trial NCT01782742?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01782742 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.